Anzu Partners

Founded 2014
Founders David Michael David Seldin Whitney Haring-Smith

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 37
Average round size
info
The average size of a deal this fund participated in
$15M
Portfolio companies 27
Rounds per year 5.29
Lead investments 14
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.30
Exits 3
Key employees 3
Stages of investment
Early Stage Venture
Private Equity

Areas of investment

  • Manufacturing
  • Biotechnology
  • Software
  • Electronics
  • Health Care
Summary

Anzu Partners appeared to be the VC, which was created in 2014. The leading representative office of defined VC is situated in the Washington. The company was established in North America in United States.

Among the most successful fund investment fields, there are Health Care, Energy Storage. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. Among the most popular portfolio startups of the fund, we may highlight MultiMechanics, TeraPore Technologies, Voltaiq. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.

The top activity for fund was in 2019. Speaking about the real fund results, this VC is 27 percentage points more often commits exit comparing to other organizations. The fund is generally included in 2-6 deals every year. The increased amount of exits for fund were in 2019. Deals in the range of 5 - 10 millions dollars are the general things for fund. Comparing to the other companies, this Anzu Partners performs on 17 percentage points less the average number of lead investments.

The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Anzu Partners, startups are often financed by VantagePoint Capital Partners, Prism Venture Management, Pivotal Investments. The meaningful sponsors for the fund in investment in the same round are Wilson Sonsini Goodrich & Rosati, RKS Ventures, Material Impact Fund. In the next rounds fund is usually obtained by Wilson Sonsini Goodrich & Rosati, Vertical Venture Partners, Triton Technology Fund.

We also calculated 3 valuable employees in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Anzu Partners:
Typical Co-investors
Anzu Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Anzu Partners:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States, Washington
Funds with similar focus located in United States, Washington:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Dropbox United States, San Francisco
Coronis Medical Ventures United States, Sunnyvale
Meritage Group LP United States, San Francisco
Compugen Israel, Tel Aviv
Integra LifeSciences United States, Plainsboro
Start Capital United Kingdom, London
Cerberian Management Group United States, American Fork
Wingspring Ventures United States, Palo Alto
Starling group -
Nabo Capital -
Lakeland Equity Partners -
Tethys Investment Management United States, Cambridge
SIIF Japan, Minato
Pengle Network Technology China, Beijing
Ontario Media Development Corporation Canada, Toronto
BIXINK Therapeutics -
Private Equity Holding Switzerland, Zug
CYTS United States, San Francisco
T2M Holding United Kingdom, London
Starling Group -
Tower Gate Capital United Kingdom, Mayfair

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

InterVenn

Biotechnology
Life Science
1
$201M02 Aug 2021 California South San Francisco United States

Niron Magnetics

Automotive
Energy
Information Technology
Manufacturing
n/a
$21M29 Jul 2021 United States, Minneapolis

Liquid Instruments

Electronics
Manufacturing
1
$13M19 May 2021 Australia Canberra

ImmunoScape

Biotechnology
Life Science
Medical
n/a
$14M14 Apr 2021 Central Singapore

Excision BioTherapeutics

Biotechnology
Health Care
Therapeutics
n/a
$60M17 Feb 2021 Pennsylvania Philadelphia United States

Excision BioTherapeutics

Biotechnology
Health Care
Therapeutics
1
02 Feb 2021 Pennsylvania Philadelphia United States

FLEx Lighting

Electronics
Hardware
Software
n/a
$9M09 Dec 2020 Chicago Illinois United States

NUBURU

Electronics
Laser
Manufacturing
1
$20M03 Dec 2020 Centennial Colorado United States

InterVenn

Biotechnology
Life Science
1
$34M16 Nov 2020 California South San Francisco United States
News
6K Raises $51M in Series C Funding

– 6K Energy is a battery developer based in Hayward, CA.
– Company raised $45m in Series B funding.
– The round was led by Volta Energy Technologies with participation from Catalus Capital, S Cap/Prithvi Ventures, Anzu Partners, Launch Capital, Material Impact and RKS Ventures.
– The new investment will be used to complete its Battery Development Center of Excellence.

InterVenn Biosciences Raises $201 Million for AI-driven Glycoproteomic Platform, Liquid-Biopsy development

– InterVenn Biosciences announced the completion of a $201m Series C financing.
– The funding round was led by new investors SoftBank Group, Heritage Provider Network, Irving Investors, Highside Capital Management, and backed by existing investors Amplify Partners, Anzu Partners, Genoa Ventures and True Ventures.
– The proceeds from the financing will be used to accelerate development and commercialization of Dawn, the company’s liquid biopsy assay for immune checkpoint inhibitor response prediction, and to expand the network of partners on the company’s AI-driven glycoproteomics platform.
– To date, the InterVenn glycoproteomics platform has been used to develop 16 clinical use cases across oncology and other indications. Dawn is currently under development and is planned to be commercialized in 2022.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Anzu Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: